Physiological considerations in the management of thyroid cancer.
D015068:17-Ketosteroids / Q000652:urine; D000293:Adolescent; D000328:Adult; D000818:Animals; D004958:Estradiol / Q000009:adverse effects; D004967:Estrogens / Q000652:urine; D005260:Female; D005500:Follow-Up Studies; D006042:Goiter / Q000188:drug therapy; D006801:Humans; D007456:Iodine Isotopes / Q000627:therapeutic use; D008297:Male; D008661:Metabolism, Inborn Errors / Q000150:complications; D051379:Mice; D009362:Neoplasm Metastasis; D010911:Pituitary Neoplasms / Q000139:chemically induced; D013902:Radiography, Thoracic; D051381:Rats; D013889:Thiouracil / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D013972:Thyrotropin / Q000502:physiology; D013974:Thyroxine / Q000627:therapeutic use; D014284:Triiodothyronine / Q000627:therapeutic use
D015068:17-Ketosteroids; D004967:Estrogens; D007456:Iodine Isotopes; D014284:Triiodothyronine; D004958:Estradiol; D013889:Thiouracil; D013972:Thyrotropin; D013974:Thyroxine